Solid Tumor Testing Market Report 2026

The solid tumor testing market size has grown strongly in recent years. It will grow from $29.94 billion in 2025 to $32.11 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to advances in cancer diagnostics, biomarker discovery, pathology automation, oncology awareness, screening initiatives.

The solid tumor testing market size is expected to see strong growth in the next few years. It will grow to $43.19 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to personalized treatment demand, early detection focus, genomic testing expansion, ai-driven diagnostics, oncology research growth. Major trends in the forecast period include growth of liquid biopsy testing, adoption of next-generation sequencing, expansion of companion diagnostics, AI-based pathology integration, increased screening programs.

The rising prevalence of cancer is expected to drive the growth of the solid tumor testing market in the coming years. Cancer is a condition characterized by abnormal cells growing and spreading uncontrollably. These cancer cells can invade surrounding tissues and organs and, in some cases, travel to other parts of the body through the bloodstream or lymphatic system. Approximately 90% of adult cancers are solid tumors. Solid tumor testing is used to detect cancer cells in the blood of patients with solid tumors, even when the cancer is not yet visible on imaging tests. For example, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, around 165,000 Australians were newly diagnosed with cancer, equating to over 450 cases per day, with males accounting for approximately 55% of these diagnoses. Therefore, the increasing prevalence of cancer is fueling the growth of the solid tumor testing market.

Key players in the solid tumor testing market are focusing on innovations such as liquid biopsy platforms for solid tumor detection. Liquid biopsy platforms involve various technologies and systems used to analyze body fluids, typically blood, for cancer-related biomarkers. For instance, in January 2023, PrognomiQ, a US-based healthcare company, launched a multi-omics liquid biopsy platform. The next phase of the company’s product development began with a 15,000-subject prospective clinical program, which enrolled its first patient. This initiative is driven by the potential of multi-omics markers to differentiate between cancer and non-cancer controls.

In June 2023, Quest Diagnostics, a US-based medical laboratory company, acquired Haystack Oncology Inc. for $450 million. Through this acquisition, Quest Diagnostics aims to expand access to liquid biopsy technologies and increase its market share in cancer diagnostics by strengthening research and development capabilities. Haystack Oncology Inc. is a US-based early-stage oncology company focused on developing solid tumor testing technologies to improve outcomes for cancer patients.

Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group.

North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the solid tumor testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the solid tumor testing market by raising prices for imported sequencing instruments, PCR systems, reagents, and diagnostic consumables. Hospitals, CROs, and pharmaceutical companies in Asia-Pacific and Europe are most affected due to heavy reliance on global diagnostics suppliers. These higher costs can slow molecular testing and early cancer detection programs. At the same time, tariffs are driving domestic diagnostic kit production, strengthening local testing capacity.

The solid tumor testing market research report is one of a series of new reports that provides solid tumor testing market statistics, including solid tumor testing industry global market size, regional shares, competitors with a solid tumor testing market share, detailed solid tumor testing market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor testing industry. This solid tumor testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Solid tumor testing involves diagnostic and molecular assessments performed on solid tumors, which are abnormal cell masses that develop in various body tissues. This testing is used to detect cancer cells or cancer-related DNA in the blood of patients with solid tumors, even when the cancer is not yet visible on imaging scans.

The primary types of solid tumor testing include genetic testing and conventional testing. Genetic testing is a medical procedure that analyzes an individual’s DNA to identify changes or variations in genes, chromosomes, or proteins. These tests are applied in the management of various cancers, including breast cancer, lung cancer, colorectal cancer, prostate cancer, and cervical cancer. They serve multiple purposes, such as clinical and research applications, and are utilized by end users including hospitals, pharmaceutical and biotechnology companies, contract research organizations, and academic research institutions.

The solid tumor testing market consists of revenues earned by entities by providing molecular profiling, next-generation sequencing, immunohistochemistry, fluorescence in situ hybridization (FISH), and biomarker testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.